Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Provided By GlobeNewswire
Last update: May 13, 2025
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025.
Read more at globenewswire.com
